MMAI is the first FDA-cleared multimodal artificial intelligence model. It’s already available for clinical use in patients. As I mentioned at the outset, it has been validated previously for benefit in women with node-negative breast cancer. This is the first study to extend that now into patients with node-positive breast cancer. So in terms of implementation, this test is already available for patients...
MMAI is the first FDA-cleared multimodal artificial intelligence model. It’s already available for clinical use in patients. As I mentioned at the outset, it has been validated previously for benefit in women with node-negative breast cancer. This is the first study to extend that now into patients with node-positive breast cancer. So in terms of implementation, this test is already available for patients. And we’re hopeful that with this validation data that was presented at ASCO this year, with the subsequent publication of that data, it will be able to be incorporated into clinical routine practice now. It is available in the United States. It’s available in Europe. This is a test that is fast, non-tissue consumptive, with a very quick turnaround time. Some of the tests that we use now to identify benefit from chemotherapy are tissue consumptive tests. That means you’ve got to send the tissue in. It’s got to be processed. You don’t get that tissue back. And it takes 7 to 14 days turnaround to get the answer that you need when you’re making a chemotherapy decision. Oftentimes, women don’t want to wait that long. And so this allows that turnaround time to be reduced significantly. It just uses an H&E slide. No tissue is sent in. And so it can be turned around really quickly. Patients and clinicians can get their answer immediately. And you can make decisions based on that. So already useful for patients with node-negative disease. Been helpful for prognosis. This is the first data to demonstrate it may be useful for node-positive patients and hopefully will be implemented soon.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
